— Why it moved
Why PPCB Stock Went Parabolic Today — June 11, 2026
A $3M preclinical pancreatic-cancer stock ran 5x on a manufacturing-deal headline, and the Stock Pulse premarket alert caught 146% of it before the fade took two thirds back.
## What moved it Propanc said it engaged a European GMP manufacturer to produce PRP, its lead pancreatic-cancer candidate, ahead of a planned Phase 1b first-in-human trial in 30 to 40 solid-tumor patients. PRP holds FDA orphan drug designation. Real news for this company, but it's trial prep, not trial data.
## The mechanics A $3 million market cap gapping 107% draws every momentum algo on the street. 175 million shares traded against a 15 million float, and volume ran to thousands of times the 30-day average. The day actually had two waves, a 5:47 AM premarket spike to $6.30 that fully collapsed, then a second, bigger run after the bell rang.
## Numbers - Cap: ~$3.1M / float: 14.9M - Day volume: 175M (~3,400x avg) - Prev close: $1.35 → gap +107% - 52w range: $1.30–$270 (reverse-split adjusted)
## Where it ended up Stock Pulse flagged it premarket at 8:36 AM at $2.76, after the first wave had deflated. It ran to $6.79 by 10:15, up 146% in 99 minutes, then spent the whole session unwinding to a $2.43 close, 12% under the alert and 64% off the top.
## Reality check - Five-bagger at the high, round trip by the close. The fade was as violent as the run. - Preclinical, no human efficacy data, and a split-adjusted 52-week high of $270 tells you how much dilution came before this. - A $3M-cap company funding a clinical trial will need more paper. This is history, not a thesis.